DiaMedica Therapeutics (DMAC) EBT (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported EBT for 9 consecutive years, with -$10.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 31.7% year-over-year to -$10.1 million; the trailing twelve-month figure through Jun 2026 stood at -$37.9 million (down 28.06% YoY), and the FY2025 full-year result was -$33.1 million, down 35.44% from the prior year.
• EBT slipped to -$10.1 million in Q2 2026 per DMAC's latest filing, from -$10.0 million in the prior quarter.
• Across five years, EBT topped out at -$3.1 million in Q3 2022 and bottomed at -$10.1 million in Q2 2026.
• Historically, EBT has averaged -$6.2 million across 5 years, with a median of -$5.2 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBT rose 11.36% in 2022, then plunged 54.29% in 2024.
• Over 5 years, EBT stood at -$3.7 million in 2022, then tumbled by 37.26% to -$5.1 million in 2023, then slumped by 54.29% to -$7.9 million in 2024, then slipped by 14.91% to -$9.1 million in 2025, then fell by 11.21% to -$10.1 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$10.1 million, -$10.0 million, and -$9.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.